Investigational drug · Phase 2
NTRX-07
Also called: MDA7
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alzheimer Disease, Mild Cognitive Impairment.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
3
Any phase or sponsor naming "NTRX-07"
First trial start
2025
Mar 1, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NTRX-07", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer Disease
- Mild Cognitive Impairment
Approved drugs for the same conditions: Alzheimer's disease · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "NTRX-07" as an intervention, largest first.
NeuroTherapia, Inc.Industry
NCT07058688 · 48 participants · Start Mar 1, 2025 · Primary completion Feb 15, 2026
Drug: NTRX-07; Placebo · For: Alzheimer Disease; Mild Cognitive Impairment
Sites: Brno, Czechia; Prague, Czechia; Budapest, Hungary · 6 sites in all
NeuroTherapia, Inc.Industry
NCT04375436 · 48 participants · Start Oct 10, 2019 · Primary completion May 15, 2020
Drug: NTRX-07-SDD · For: Pain, Neuropathic
Sites: Tustin, California
NeuroTherapia, Inc.Industry
NCT06194552 · 32 participants · Start Sep 6, 2022 · Primary completion May 31, 2023
Drug: NTRX-07; Placebo · For: Alzheimer Disease
Sites: Gates Mills, Ohio; Kistarcsa, Hungary
Newest research
PubMed records naming it or its code names, newest first.
- Chloroquine Enhances Mda-7- Induced Apoptosis via miR-7 and HSP70 Modulation in Glioblastoma.
Babazadeh SM, Zolfaghari MR, Zargar M, et al. · Iran Biomed J 2025
- Pro-inflammatory effects of endogenous and recombinant MDA-7/IL-24 with RGD peptide on human hepatic stellate cells.
Daneshparvar A, Hosseini SY, Hamidizadeh N, et al. · Sci Rep 2025
- Characterization of Novel and Known Activators of Cannabinoid Receptor Subtype 2 Reveals Mixed Pharmacology That Differentiates Mycophenolate Mofetil and GW-842,166X from MDA7.
Rodriguez AL, Qi A, Han A, et al. · Int J Mol Sci 2025
- In vitro activation of anti-cancer gene expression by delivery of CRISPR/dCas9 ribonucleoproteins to suppress glioblastoma.
Lee MH, Thomas JL, Lin YL, et al. · Int J Biol Macromol 2025
- PIKFYVE inhibitors trigger interleukin-24-dependent cell death of autophagy-dependent melanoma.
Roy A, Chakraborty AR, DePamphilis ML · Mol Oncol 2024
- The investigation of the death-inducing potency of a recombinant Adenovector expressing Mda-7-tlyp-1 on different cancer cell lines.
Vatanparast F, Ghojoghi R, Kadkhodazadeh M, et al. · Gastroenterol Hepatol Bed Bench 2024
Also in development for Alzheimer Disease
- KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials
Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder
- ITI-1284JNJ-99245354Phase 36 trials
Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders
- AXS-05dextromethorphan-bupropionPhase 33 trials
Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- Combined metabolic activatorsPhase 32 trials
ScandiBio Therapeutics AB · Alzheimer Disease, Gout Disease
- DMB-IINN: Latrepirdine, DimebonPhase 32 trials
Bigespas LTD · Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type
- AR1001Phase 31 trial
AriBio Co., Ltd. · Alzheimer Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.